W.G. Shaheen & Associates Dba Whitney & CO Affimed N.V. Call Options Transaction History

W.G. Shaheen & Associates Dba Whitney & CO

$856 Million
Q2 2024

Call Options

0 transactions

Quarter	Operation	Price Per call	calls change	calls Held	SEC Form

No transaction found.

Others Institutions Holding AFMD

# of Institutions

Shares Held

1.09M

Call Options Held

Put Options Held

Tekla Capital Management LLC

586K
Shares

$1.91 Million
0.01% of portfolio
Act Capital Management, LLC Wayne, PA

309K
Shares

$1.01 Million
0.88% of portfolio
Telemetry Investments, L.L.C. New York, NY

200K
Shares

$652,000
0.39% of portfolio

View Full List

About Affimed N.V.

Ticker AFMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,339,008
Market Cap $487M
Description
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...

More about AFMD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of W.G. Shaheen & Associates Dba Whitney & CO, based on Form 13F filings with the SEC.

News

Stay updated on W.G. Shaheen & Associates Dba Whitney & CO with notifications on news.

Account